Home

  • Order to parcel locker

    Order to parcel locker

  • easy pay

    easy pay
  • Reduced price

Cancer Chemotherapy and Biological Response Modifiers

Annual 21

9780444514585
937.44 zł
843.70 zł Save 93.74 zł Tax included
Lowest price within 30 days before promotion: 843.70 zł
Quantity
Product unavailable
Out of print

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description
Cancer Chemotherapy & Biological Response Modifiers Annual 21 contains an expanded section on Colorectal Cancer, an area that has seen remarkable progress in screening, early detection, prevention and therapy in just the last few years. Annual 21 also includes updates on biology and treatment of common malignancies as well as chapters that summarise recent advances in chemotherapy and immunotherapy for cancer.
Product Details
Mosby
30926
9780444514585
9780444514585

Data sheet

Publication date
2003
Issue number
1
Cover
hard cover
Pages count
916
Weight (g)
2177
  • Section 1: Drugs Thymidylate synthase inhibitors (SP Ackland, P Beale, GJ Peters); Anthracyclines (L Gianni, G Grasselli, S Cresta, A Locatelli, L Vigano, G Minotti); Tubulin-targeting agents (WN Hait, E Rubin, S Goodin); Topoisomerase I interactive agents (PK Turner, LC Iacono, CF Stewart); Topoisomerase II inhibitors (KR Hande); Farnesyltransferase inhibitors (AA Adjei); Cyclin-dependent kinases as targets for cancer therapy (MA Shah, GK Schwartz); DNA-binding agents (Y Nieto); Advances in endocrine therapy for the treatment and prevention of breast cancer (WJ Gradishar, VC Jordan)

    Section 2: Biological Response Modifiers Monoclonal and antibody therapy for breast cancer: Herceptin (RS Finn, DJ Slamon); Rituximab (P Multani, CA White); Mucins in gastrointestinal cancers (MS Turner, JR McKolanis, RK Ramanathan, DC Whitcomb, OJ Finn); HER-2/neu vaccines (ML Disis, K Schiffman, LG Salazar, B Almand, KL Knutson); Colon cancer antigen and anti-idiotype vaccines (D Herlyn, B Birebent, N Akis, E Purev, R Somasundaram, E Mitchell, H Maguire, L Staib, M Mastrangelo); Anti-carcinoembryonic antigen immunity (M DeBenedette, L Radvanyi, D Singh-Sandhu, NL Berinstein); Cancer gene therapy and immunotherapy (Y Kawakami, TJ Curiel, DT Curiel); Recent areas of development for dendritic cell vaccines (MA Morse, S Chui, TM Clay, HK Lyerly); Mechanisms of tumour evasion from the immune response (PC Rodriguez, AH Zea, AC Ochoa).

    Section 3: Tumours Plasma cell myeloma and leukemia (PH Wiernik); Lymphomas (A Santoro, L Castagna, M Magagnoli); Head and neck cancers (M Al-Sarraf, X Guo); Lung cancer (G Giaccone, E Smit); Upper gastrointestinal tumours (K Aiba, M Ogawa); Cancers of the large bowel and hepatobiliary tract (W Sun, D Haller); Neuroendocrine tumours - somatostatin receptor expression and somatostatin analog treatment (E Tiensuu Janson, K Oberg); Genitourinary malignancies (MD Michaelson, MR Smith); Systematic therapy for gynaecological neoplasms: ovary, cervix and endometrium (S Pecorelli, R Angioli, G Favalli, F Odicino); Breast cancer (P Valagussa, G Bonadonna); Melanoma - new developments in diagnosis and therapy (A Schneeberger, SN Wagner); Sarcoma (M Scurr, I Judson); Brain tumors (JK Pueschel, LS Ashby, WR Shapiro); Biology and therapy of malignant solid tumors in childhood (H van den Berg); Supportive care (M Markman); AIDS-associated malignancies (MH Shah, P Porcu, SR Mallery, MA Caligiuri).

    Special Section: Colorectal Cancer Risk assessment and screening for colorectal cancer (KE Kim); Non-steroidal and anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention (ET Hawk, J Viner, E Richmond, A Umar); Molecular predictors of prognosis and response to therapy in colorectal cancer (HL McLeod; RD Church); Combined modality therapy for rectal cancer (BD Minsky); New drugs for colorectal cancer (PMG Hoff); Liver directed therapies for colorectal cancer (AS Wright, DM Mahvi).
Comments (0)

  • Frequently purchased together

    No products available